A recent study with a longer follow-up period of 3 years has demonstrated that IL-2 + IFN-γ/IL-10 + IL-4 ratio was significantly elevated in those patients with RRMS that suffered from relapses and progressing brain atrophy, suggesting that a specific pattern of Th2/Th1 cytokines may predict clinical response to GA therapy [33]. The gene discussed is IFNG; the disease is Brain atrophy.